Co-Authors
This is a "connection" page, showing publications co-authored by SUE-HWA LIN and NORA M NAVONE.
Connection Strength
1.053
-
Radium-223 Treatment Produces Prolonged Suppression of Resident Osteoblasts and Decreased Bone Mineral Density in Trabecular Bone in Osteoblast Reporter Mice. Cancers (Basel). 2024 Jul 21; 16(14).
Score: 0.242
-
Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J Pathol. 2010 May; 221(1):68-76.
Score: 0.090
-
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest. 2008 Aug; 118(8):2697-710.
Score: 0.080
-
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008 Jun 15; 14(12):3729-36.
Score: 0.079
-
A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene. 2008 Sep 04; 27(39):5195-203.
Score: 0.079
-
Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res. 2008 Mar 15; 14(6):1599-602.
Score: 0.078
-
Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene. 2008 Jan 24; 27(5):596-603.
Score: 0.075
-
A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res. 2007 Jul 15; 67(14):6544-8.
Score: 0.074
-
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun. 2023 12 13; 3(12):2531-2543.
Score: 0.058
-
Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. Prostate Cancer Prostatic Dis. 2023 Dec; 26(4):751-758.
Score: 0.053
-
Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res. 2021 06 01; 27(11):3253-3264.
Score: 0.048
-
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999.
Score: 0.044
-
Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci U S A. 2015 Mar 24; 112(12):3776-81.
Score: 0.032
-
Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res. 2007 Jul; 5(7):675-84.
Score: 0.019